|Bid||108.04 x 800|
|Ask||108.10 x 800|
|Day's range||106.58 - 108.33|
|52-week range||63.22 - 108.33|
|Beta (5Y monthly)||0.27|
|PE ratio (TTM)||36.66|
|Forward dividend & yield||1.47 (1.45%)|
|Ex-dividend date||16 Aug 2021|
|1y target est||106.36|
With that in mind, let's turn our attention to two healthcare giants with excellent track records -- Medtronic (NYSE: MDT) and Novo Nordisk (NYSE: NVO) -- and see why both companies may be well worth holding onto for the years ahead. Like many other medical-device specialists, Medtronic had a rough go of it at the peak of the pandemic. Healthcare facilities swamped with COVID-19 patients postponed elective surgeries, leading to lower sales volume for some of Medtronic's products used by physicians.
It's not that difficult to spread your investments out across many companies and hope for the best over a long time horizon. Another took a different route by making a bet on ARK Genomic Revolution ETF (NYSEMKT: ARKG) in the hope of owning the first healthcare industry trillion-dollar market cap company. Jason Hawthorne (Novo Nordisk): Novo Nordisk is one of three large drug manufacturers that account for the majority of insulin production in the world.
GSK vs. NVO: Which Stock Is the Better Value Option?